However, there is little disruption of HER2-HER3 signaling afforded by targeting the ECDs in HER2-overexpressing tumor cells (Campbell et al., 2022), and these approaches pursue a different mechanistic path. The gene discussed is ERBB3; the disease is neoplasm.